Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD79A & CD79B

CD79A & CD79B

Brief Information

Name:B-cell antigen receptor complex-associated protein beta chain
Target Synonym:B-Cell Antigen Receptor Complex-Associated Protein Beta Chain,B29,Immunoglobulin-associated B29 protein,Ig-beta,B-cell-specific glycoprotein B29,CD79B,CD79b Molecule,CD79b Molecule, Immunoglobulin-Associated Beta,IGB,CD79B Antigen (Immunoglobulin-Associated Beta),CD79b Antigen,AGM6
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

SCCHO-ATP170-Cell-based assay
 CD79A & CD79B FACS

Expression analysis of human CD79A on CHO/Human CD79A&CD79B Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human CD79A&CD79B Stable Cell Line or negative control cell using FITC-labeled anti-human CD79A antibody.

SCCHO-ATP170-Cell-based assay
 CD79A & CD79B FACS

Expression analysis of human CD79B on CHO/Human CD79A&CD79B Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human CD79A&CD79B Stable Cell Line or negative control cell using APC-labeled anti-human CD79B antibody.

CDB-H52W3-MALS-HPLC
CD79A & CD79B MALS images

The purity of Human CD79A&CD79B Heterodimer Protein, Mouse IgG2a Fc,Flag Tag&Mouse IgG2a Fc,His Tag (Cat. No. CDB-H52W3) is more than 85% and the molecular weight of this protein is around 110-150 kDa verified by SEC-MALS.

CDB-H52W3-ELISA
 CD79A & CD79B ELISA

Immobilized Human CD79A&CD79B Heterodimer Protein, Mouse IgG2a Fc,Flag Tag&Mouse IgG2a Fc,His Tag at 1 μg/mL (100 μL/well) can bind Polatuzumab with a linear range of 0.1-1 ng/mL (QC tested).

CD79A & CD79B Molecule Synonym Name

CD79A&CD79B, B-cell antigen receptor complex-associated protein alpha chain, B-cell antigen receptor complex-associated protein beta chain

CD79A & CD79B Molecule Background

CD79a and CD79b heterodimers are the important signaling components of B cell receptor (BCR) complex which plays a crucial role in B cell development and antibody production. BCR complexes are composed of a ligand-binding receptor (membrane immunoglobulin; mIg), non-covalently associated with the signaling com-ponent, a disulfide-linked heterodimer of CD79a (Igα) and CD79b (Igβ). Both CD79 subunits consist of an Ig-like domain, a transmembrane (TM) region, and a longer cytoplasmic tail (CYT) containing an immune-receptor tyrosine-based activation motif (ITAM).

CD79A & CD79B References

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Polatuzumab vedotin RO-5541077-000; FCU-2711; DCDS-4501A; RG-7596; RO-5541077 Approved Seattle Genetics Inc, Genentech Inc Polivy United States Lymphoma, Large B-Cell, Diffuse Genentech Inc 2019-06-10 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
TolDCB29 Phase 2 Clinical Umc Utrecht Arthritis, Rheumatoid Details
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR CD19/79b Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
CD79b-19 CAR T Cells Therapy (Massachusetts General Hospital) Massachusetts General Hospital Details
Iladatuzumab vedotin DCDS-0780A; RO-7032005 Phase 1 Clinical F. Hoffmann-La Roche Ltd Lymphoma, Non-Hodgkin Details
CD79b CAR-T cell therapy (Yake Biotechnology) Phase 1 Clinical Zhejiang University Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Biphenotypic, Acute Details
PRV-3279 HDM-3002; MGD-010; PRV-3279; CD32BxCD79B Phase 2 Clinical Macrogenics Inc Drug-Related Side Effects and Adverse Reactions; Lupus Erythematosus, Systemic Details
Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy(MD Anderson Cancer Center) JV-213 Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Lymphoma, B-Cell; Lymphoma Details
NBT-508 Phase 1 Clinical Newbio Therapeutics Inc Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
SHR-A1912 SHR-A1912 Phase 2 Clinical Shanghai Hengrui Pharmaceutical Co Ltd Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message